New imaging technique for age-related macular degeneration
Snapshot 3D Ultra-high-resolution OCT and Hyperspectral AF of In-vivo Retina
This study is testing a new imaging tool to see if it can help doctors get better pictures of the retina in people with early to intermediate age-related macular degeneration, which could lead to earlier diagnosis and better understanding of the condition.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 60 Years to 90 Years |
| Sex | All |
| Sponsor | Icahn School of Medicine at Mount Sinai Academic / other |
| Locations | 1 site (New York, New York) |
| Trial ID | NCT03963817 on ClinicalTrials.gov |
What this trial studies
This study aims to utilize a novel imaging instrument that combines adaptive optics with optical coherence tomography and autofluorescence to capture detailed images of the retinal pigment epithelium in individuals with age-related macular degeneration (AMD). By providing both structural and molecular insights into the retina, this approach seeks to enhance early diagnosis and understanding of AMD, which is a leading cause of blindness. The technology promises to overcome limitations of traditional imaging methods, allowing for improved visualization of retinal cells in vivo and in 3D. The study will involve normal subjects and those diagnosed with early to intermediate AMD.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals aged 60 and over who have been diagnosed with early or intermediate AMD in at least one eye.
Not a fit: Patients with advanced AMD, other forms of retinopathy, or those unable to provide informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this imaging technique could lead to earlier diagnosis and better management of age-related macular degeneration, potentially slowing vision loss.
How similar studies have performed: Other studies have shown promise with advanced imaging techniques for AMD, but this specific approach integrating adaptive optics and hyperspectral imaging is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients must be aged 60 and over and pseudophakic, with clear posterior capsule and dilation to 6mm. * Patients must be diagnosed early/intermediate AMD in at least one eye (the study eye) with soft drusen or reticular pseudodrusen in the macula. Exclusion Criteria: * Retinopathy other than AMD. * Inability to give informed consent * Bilateral advanced AMD * Allergy to dilation eye drops
Where this trial is running
New York, New York
- New York Eye and Ear Infirmary of Mount Sinai — New York, New York, United States (Recruiting)
Study contacts
- Principal investigator: Ronald Theodore Smith, MD, PhD — Icahn School of Medicine at Mount Sinai
- Study coordinator: Katy Tai
- Email: ktai@nyee.edu
- Phone: 212-979-4251
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.